PATENT CLAIM ANALYSIS

Application Number: 16047372
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-02
Patent Classification: ["514", "266200"]

Abstract:
Novel 2,4-diaminoquinazoline derivatives are disclosed. The compounds can be used in treating diseases and conditions which are associated with abnormal cell function related to endoplasmic reticulum (ER) stress. For example, the compounds can be used as suppressors of ER stress-induced pancreatic β-cell dysfunction and death, for example in the treatment of diabetes.

Claim (Index 18):
The compound of  claim 1  linked to a targeting molecule, wherein the targeting molecule is able to bind to a target cell or a portion of a target cell.

Metadata:
- Claim Count in Document: 13.0
- Percentile: 95.0
- Lexical Diversity: 1.31111
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14670088', '14786561', '13484702', '16011090', '15346443']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7686400131889579
- 35 USC 102 Novelty (BERT): 0.5036107102076349
- Combined Prediction Score: 0.7421370828908256
- Mean Citation Score: 218.25733
- Max Citation Score: 226.46878
- Similarity Product: 145.92130954509497

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test